ICG-001 manufacturers
- ICG-001
-
- $30.00
-
2026-04-22
- CAS:780757-88-2
- Purity: 99.59%
- Supply Ability: 10g
- ICG-001
-
- $1.00
-
2020-01-14
- CAS:780757-88-2
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 200kg
|
| | ICG-001 Basic information |
| Product Name: | ICG-001 | | Synonyms: | (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide;(6S,9aS)-6-(4-hydroxybenzyl)-N-benzyl-8-(naphthalen-1-ylmethyl)-4,7-dioxo-hexahydro-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide;ICG-001;ICG001;(6S,9AS)-6-(4-HYDROXYBENZYL)-N-BENZYL-8-(NAPHTHALEN-1-YLMETHYL)-4,7-DIOXO-HEXAHYDRO-2H-PYRAZINO[1,2-A]PYRIMIDINE-1(6H)-CARBOXAMIDE;2H-PYRAZINO[1,2-A]PYRIMIDINE-1(6H)-CARBOXAMIDE,HEXAHYDRO-6-[(4-HYDROXYPHENYL)METHYL]-8-(1-NAPHTHALENYLMETHYL)-4,7-DIOXO-N-(PHENYLMETHYL)-,(6R,9AR)-REL-;(6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylMethyl)-;(6S,9AS)-6-(4-HYDROXYBENZYL)-8-NAPHTHALEN-1-YLMETHYL-4,7-DIOXO-HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-1-CARBOXYLIC ACID BENZYLAMIDE;(6S,9aS)-rel-Hexahydro-6-[(4-hydroxyphenyl)Methyl]-8-(1-naphthalenylMethyl)-4,7-dioxo-N-(phenylMethyl)-2H-pyrazino[1,2-a]pyriMidine-1(6H)-carboxaMide;(S,S)-ICG 001 | | CAS: | 780757-88-2 | | MF: | C33H32N4O4 | | MW: | 548.63 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 780757-88-2.mol |  |
| | ICG-001 Chemical Properties |
| Melting point | 133-134℃ | | Boiling point | 895.6±65.0 °C(Predicted) | | density | 1.37 | | storage temp. | Store at -20°C | | solubility | DMSO:30.0(Max Conc. mg/mL);54.68(Max Conc. mM) | | form | A crystalline solid | | pka | 9.88±0.15(Predicted) | | color | White to off-white | | InChIKey | HQWTUOLCGKIECB-XZWHSSHBSA-N | | SMILES | [C@]12([H])CN(CC3=C4C(C=CC=C4)=CC=C3)C(=O)[C@H](CC3=CC=C(O)C=C3)N1C(=O)CCN2C(NCC1=CC=CC=C1)=O |
| | ICG-001 Usage And Synthesis |
| Uses | ICG 001 is a small molecule inhibitor of Wnt/β-catenin signaling. | | Definition | ChEBI: (6S,9aS)-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide is a peptide. | | in vivo | ICG-001 (5 mg/kg per day) significantly inhibits beta-catenin signaling in mice, while concurrently preserving the epithelium[2]. Administration of a water-soluble analog of ICG-001 for 9 weeks reduces the formation of colon and small intestinal polyps by 42% as effectively as the nonsteroidal antiinflammatory agent MK-231, which has consistently demonstrated efficacy in this model. ICG-001 (150 mg/kg, i.v.) demonstrates a dramatic reduction in tumor volume over the 19-day course of treatment, with no mortality or weight loss in the SW620 nude mouse xenograft model of tumor regression[3]. | | storage | -20°C |
| | ICG-001 Preparation Products And Raw materials |
|